All In Biotech

Drug Trial Radar · NCT04254107

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

133

Actual

Start

May 29, 2020

Primary completion

Dec 1, 2023

Study completion Dec 1, 2023

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).

Conditions

  • Non-small Cell Lung Cancer
  • Gastric Carcinoma
  • Gastroesophageal Junction Carcinoma
  • Classical Hodgkin Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Peripheral T-cell Lymphoma
  • Cutaneous Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Bladder Cancer
  • Ovarian Cancer
  • Triple Negative Breast Cancer
  • Cervical Cancer

Interventions

  • SEA-TGTDrug

    Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle

  • sasanlimabDrug

    Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle

  • brentuximab vedotinDrug

    Given by IV on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
  2. Number of participants with laboratory abnormalities by gradeTime frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
  3. Number of participants with a dose-limiting toxicity (DLT) at each dose levelTime frame: Up to 21 days

Locations

36 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Oncology Associates, PC - HOPE

    Tucson, Arizona

  • City of Hope

    Duarte, California

  • California Research Institute

    Los Angeles, California

  • University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

    San Francisco, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Johns Hopkins Medical Center

    Baltimore, Maryland

  • Maryland Oncology Hematology, P.A.

    Rockville, Maryland

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Minnesota Oncology Hematology P.A.

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Weill Cornell Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Wake Forest Baptist Medical Center / Wake Forest University

    Winston-Salem, North Carolina

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology - Austin Midtown

    Austin, Texas

  • Texas Oncology - Baylor Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center / University of Texas

    Houston, Texas

  • Texas Oncology - Northeast Texas

    Tyler, Texas

  • Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care

    Blacksburg, Virginia

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Carbone Cancer Center / University of Wisconsin

    Madison, Wisconsin

  • University of Alberta / Cross Cancer Institute

    Edmonton, Alberta, Canada

  • University Health Network, Princess Margaret Hospital

    Toronto, Other, Canada

  • Institut Gustave Roussy

    Villejuif, Other, France

  • Istituto Europeo di Oncologia

    Milan, Other, Italy

  • Policlinico Universitario Agostino Gemelli

    Rome, Other, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Other, Spain

  • L'Institut Catala d'Oncologia

    L'Hospitalet de Llobregat, Other, Spain

  • HM Centro Integral Oncologico Clara Campal

    Madrid, Other, Spain

  • Sarah Cannon Research Institute UK

    London, Other, United Kingdom

  • The Royal Marsden Hospital (Surrey)

    Sutton, Other, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.